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Introduction
Of the global population of patients with type 2 diabetes, 
approximately half have signs of chronic kidney disease 
(CKD).1 Any successful early intervention that reduces or 
delays progression in diabetic kidney disease is therefore 
expected to have a major impact on life expectancy and 
quality of life, as well as chronic care health economic 
costs. Primary prevention of microalbuminuria could be 
such an early intervention, that might truly prevent com-
plications. This intervention would contrast to what is 
most frequently provided: treatment after the first signs of 
damage is present.
A major part of the chronic care of patients with type 2 
diabetes is focused on the prevention of complications 
such as diabetic kidney disease. Specifically, the use of 
angiotensin-converting enzyme inhibitors (ACEis) or 
angiotensin II receptor blockers (ARBs) is recommended2 
in the presence of microalbuminuria/moderately increased 
(urinary albumin creatinine ratio (UACR)>30 mg/g and 
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Abstract
Hypothesis/objectives: Early prevention of diabetic nephropathy by way of blocking the renin-angiotensin system 
(RAS) in patients with normoalbuminuria seems rational, but trials have so far shown conflicting results. The present 
meta-analysis was undertaken to investigate if such treatment can prevent development of microalbuminuria.
Materials and methods: We searched MEDLINE, EMBASE and the Cochrane Library (2 June 2014) for randomised 
controlled trials, with a population of patients with type 2 diabetes and normoalbuminuria, comparing angiotensin-
converting enzyme inhibitors (ACEis) or angiotensin receptor blockers (ARBs) to placebo. Studies had to have at least 
50 participants in each arm and one year of follow-up. Random and fixed effect models were performed as well as trial 
sequential analysis.
Results: Six trials were included in the analysis (n=16,921). Overall risk of bias was variable. In a fixed model analysis 
ACE or ARB treatment was superior to placebo in relation to prevention of development of microalbuminuria, risk ratio 
0.84 (95% confidence interval (CI) 0.79–0.88) p<0.001, I2=23%, similar to random model results. Treatment also showed 
a trend towards a reduction in all-cause mortality(p=0.07).
Conclusions: We conclude that in patients with type 2 diabetes and normoalbuminuria, early intervention with ACEis 
or ARBs reduces the risk for development of microalbuminuria.
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<300 mg/g) or macroalbuminuria/severely increased 
(UACR>300 mg/g). The intervention leads to decreased 
albuminuria, prevents progression from microalbuminuria 
to macroalbuminuria and results in a reduced risk of 
cardiovascular disease (CVD), end stage renal disease 
(ESRD) and death.
Only a few studies have been conducted with primary 
prevention of albuminuria as outcome, and with conflict-
ing results.3–5 Currently there is no recommendation2 for 
the use of renin-angiotensin system (RAS) inhibitors for 
primary prevention of the occurrence of albuminuria in 
patients with type 2 diabetes. Previous attempts to sum-
marise studies, including a Cochrane analysis6 have 
combined type 1 and type 2 diabetes, which may not be 
appropriate given the heterogeneity in kidney pathology. 
Diabetic nephropathy in type 1 diabetes is considered to be 
strictly a glomerular pathology with microalbuminuria as 
an early herald of molecular and cellular changes. In pro-
teinuric type 2 diabetes, however, the causes of nephropa-
thy are heterogenous.7–9 This warrants a separate analysis 
in type 2 diabetes. In addition, the recent Cochrane analy-
sis investigated antihypertensive treatment in general and 
not exclusively studies using ACEi or ARBs.6
The aim of our analysis was therefore not only to spe-
cifically assess the effect on development of microalbumi-
nuria with intervention with an ACEi or ARB in patients 
with type 2 diabetes and normoalbuminuria, but also to try 
to assess whether further studies are needed. By presenting 
such a review of findings, we hope to assist clinicians in 
order to be better informed regarding treatment decisions.
Materials and methods
We searched MEDLINE, EMBASE and the Cochrane 
Library (2 June 2014), and search strings are included in the 
Supplementary Material. The protocol with details for this 
meta-analysis was published on the PROSPERO website 
(http://www.crd.york.ac.uk/PROSPERO/) (PROSPERO 
CRD42014009983) ahead of the initiation of the literature 
search. In summary, in order to be included in our analysis 
studies had to be double-masked randomised controlled tri-
als, with a population of patients with type 2 diabetes and 
normoalbuminuria (UACR<30 mg/g) or urinary albumin 
excretion rate (UAER)<30 mg/24 h). In order to assess the 
effect of RAS inhibition, we only included studies compar-
ing ACEi or ARB to placebo. At least one year of follow-up 
was considered necessary for evaluation of the effect on 
development of micro- or macroalbuminuria, and studies 
had to have at least 50 participants in each arm. The primary 
outcome for our analysis was development of micro/mac-
roalbuminuria defined as UACR>30 mg/g or UAER>30 
mg/24 h or corresponding converted units.
Our intention was also to investigate secondary outcomes 
including all-cause mortality, total CVD mortality (death 
from myocardial infarction, stroke and peripheral vascular 
disease) and CVD morbidity (non-fatal myocardial infarc-
tion, non-fatal stroke, amputation of lower extremity and 
coronary or peripheral revascularisation). In addition renal 
outcomes defined as doubling of baseline serum creatinine 
or progression to ESRD was investigated.
Selection of studies
An independent experienced librarian performed the initial 
literature search. Studies were included in the meta-analy-
sis after full agreement between two authors (FP and ML).
Assessment of risk of bias in included studies
Two authors (FP and ML) independently assessed the 
risk of bias in each trial by means of the Cochrane 
Collaboration’s risk of bias tool.
Measures of treatment effect
Data on dichotomous outcomes were statistically summa-
rised as relative risks (RRs) with 95% confidence intervals 
(CIs).
Assessment of heterogeneity
A priori the authors evaluated clinical heterogeneity of the 
included trials. Heterogeneity was identified by visual 
inspection of the forest plots, by using a standard chi2 test 
with a significance level of α=0.1. Heterogeneity was spe-
cifically examined with the I 2 statistic, where I 2 values of 
0–40% indicate heterogeneity might not be important; 
30–60% may represent moderate heterogeneity; 50–90% 
may represent substantial heterogeneity; and 75–100% 
may represent considerable heterogeneity.10
Assessment of overall effect on outcome
We used both a random effects model11 and a fixed effect 
model12 with no a priori consideration regarding which 
model to consider as primary model.
Data extraction and management
Two authors (FP and ML) independently extracted infor-
mation on each trial using standard data extraction forms. 
The forms included data concerning trial design, partici-
pants, interventions and outcomes as detailed in the selec-
tion criteria described above.
Data synthesis
Statistical analysis was performed according to the statisti-
cal guidelines in the newest version of The Cochrane 
handbook for systematic reviews of interventions.10 
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Calculations and modelling were performed using the 
RevMan software version 5.3. The effect of treatment is 
calculated as risk ratios (RRs) and reported with 95% CIs, 
with a p-value <0.05 considered statistically significant.
Trial sequential analysis (TSA)
TSA is a methodology that combines an information size 
calculation (cumulated sample sizes of included trials) for 
meta-analysis with the threshold of statistical significance. 
TSA is a tool for quantifying the statistical reliability of 
data in a cumulative meta-analysis adjusting p-values for 
repetitive testing on accumulating data. TSA was con-
ducted on the outcomes showing statistical significance in 
both random effects and fixed effect model.13,14
We applied TSA since it prevents an increase of the risk 
of type I error (less than 5%) due to potential multiple 
updating in a cumulative meta-analysis and provides 
important information in order to estimate the level of evi-
dence of the experimental intervention. We applied trial 
sequential monitoring boundaries according to an informa-
tion size suggested by the intervention effect estimated 
based on an a priori 10% relative risk reduction (RRR) 
employing α=0.05 and ß=0.20.
We used TSA version 0.9 beta for these analyses 
(Copenhagen Trial Unit, Trial Sequential Analysis (com-
puter program), version 0.9 beta, Centre for Clinical 
Intervention Research, 2011, www.ctu.dk/tsa).
Subgroup analyses
Subgroup analyses according to hypertension status were 
initially planned for the primary outcome, but this approach 
was abandoned during the data analysis process owing to 
different and missing definitions of hypertension threshold 
in the included studies.
Results
A flow diagram of the numbers of studies identified and 
rejected at each stage in accordance with Preferred 
Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) statement15 can be seen as Figure 1. 
In brief, an experienced academic librarian searched and 
found 64 abstracts from MEDLINE, EMBASE and the 
Cochrane Library, and these underwent thorough evalua-
tion in relation to inclusion criteria for this analysis. In 
addition, 1035 abstracts that were not captured in the ini-
tial search were screened, but no further studies fulfilling 
inclusion criteria were identified. Authors were not con-
tacted for further data from any of the included studies.
We included six randomised controlled clinical 
trials3–5,16–18 in our meta-analysis, and their characteristics 
can be seen in Table 1 (n=16,921 patients). Based on the 
inclusion criteria chosen for this analysis, the number of 
trials were considerably lower than a previous Cochrane 
metanalysis on the subject.6 The overall risk of bias was 
variable (Figure 2).
In fixed model analysis, ACEi or ARB treatment was 
superior to placebo in order to prevent development of 
microalbuminuria, with a risk ratio of 0.84 (95% CI 0.79–
0.88) p<0.001. In the random model the results showed a 
risk ratio of 0.84 (0.78–0.91) p<0.001. There was no sign 
of heterogeneity in the risk ratio outcome with a I 2=23%, 
p=0.26. Forest plots are presented in Figure 3(a) and (b).
In the trials included as well as in the abstracts screened 
there were insufficient data available for the originally 
intended calculation of secondary outcomes, except for 
all-cause mortality shown in Figure 4, in which ACEi/
Figure 1. Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) chart.
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Table 1. Characteristics of the included studies.
Study Year Patients 
(n)
Follow-up 
(years)
RAS blocking 
agent
Daily dose 
(mg)
Hard renal outcome 
reported (yes/no)
Ravid et al.16 1998 156 6 Enalapril 10 No
MICROHOPE17 2000 3577a 4.5 Ramipril 10 Yes
BENEDICT3 2004 1204 3.6 Trandolapril 2 No
DIRECT 24 2009 1905 4.7 Candesartan 32 No
ADVANCE18 2009 11,140 4.3 Perindopril 2 Yes
ROADMAP5 2011 4447 3.2 Olmesartan 40 Yes
RAS: renin-angiotensin system.
aTotal no. of included patients in the study. Approximately 30% had microalbuminuria at baseline and were excluded from this analysis.
Figure 2. Risk of bias as evaluated by the authors. (a) risk of bias item for each included study. (b) risk of bias item presented as 
percentages across all included studies.
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Figure 3. (a) Fixed and (b) random model forest plots of the effect of angiotensin-converting enzyme inhibitor (ACEi)/angiotensin 
receptor blocker (ARB) therapy vs placebo to prevent microalbuminuria in type 2 diabetes.
Figure 4. (a) Fixed and (b) random model forest plots of the effect of angiotensin-converting enzyme inhibitor (ACEi)/ angiotensin 
receptor blocker (ARB) therapy vs placebo on mortality in patients with type 2 diabetes and normoalbuminuria.
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ARB treated tended to reduce mortality, RR 0.91(0.83–
1.01) p=0.07.
The populations included in the six trials were a mix of 
normotensive and hypertensive, with differing definitions 
or thresholds for hypertension. The fraction of hyperten-
sive subjects ranged from 0–100 %, see Table 2 for an 
overview of hypertension status in the six trials. It was not 
possible to conduct subgroup analysis of effect of the 
intervention according to baseline normotension vs hyper-
tension, but approximately 38% of included patients were 
normotensive, or at least 31% if all subjects from the 
MICRO-HOPE study17 are considered hypertensive.
Trial sequential analysis revealed a Z-value of 6.53 and 
an information size of 4163 patients (O’Brien two-sided 
5% boundaries), indicating that the available studies and 
the available data in our analysis are sufficient to make 
these investigations and conclusions (Supplementary 
Material, Figure 1). For all secondary outcomes except all-
cause mortality, numbers in the included studies were too 
small to be analysed in our review.
Discussion
In our meta-analysis of studies testing whether ACEi/
ARB treatment, compared to placebo, can prevent devel-
opment of microalbuminuria in type 2 diabetic patients, 
we identified six trials including 16,921 normoalbuminu-
ric patients with type 2 diabetes. We found a 16% RR 
reduction for development of microalbuminuria in the 
ACE/ARB treatment group as compared to placebo 
groups. The findings were significant both in random 
effects and fixed effect models, although given the clini-
cal heterogeneity of the studies, the random model prob-
ably can be considered the most robust. The risk ratio of 
0.84 corresponds to a number needed to treat (NNT) of 
25, meaning that for every 25 normoalbuminuric patients 
treated with ACEi/ARB, one case of microalbuminuria 
will be prevented or delayed (although the required 
treatment time needed cannot be determined from this 
analysis). From a recent paper from Schievink et al.19 it is 
simulated that early RAS blockade intervention, as in the 
present analysis, can postpone ESRD by 4.2 years, com-
pared to later stage interventions (3.6 and 1.1 years, for 
micro-and macroalbuminuria, respectively). Based on 
the TSA the available information size was found suffi-
cient to support the inclusion, which means that it could 
be considered unethical to do further trials investigating 
this treatment compared to placebo.
The importance of change in albuminuria is evident 
from analyses of the IRMA2 study20 and the Steno 2 
study,21 where reduction in albuminuria, and regression of 
micro- to normoalbuminuria translated into preserved kid-
ney function. The primary outcome in our review is a sur-
rogate outcome, and not a hard renal endpoint as i.e. 
ESRD, but the studies available do not have enough fol-
low-up time to allow for hard renal endpoint evaluation. 
Our primary outcome is however frequently used clini-
cally, and is a simple way to assess not only renal but also 
cardiovascular risk.
In type 2 diabetes the RAS is activated and has long 
been thought to play a major part in development of 
chronic vascular complications, including diabetic 
nephropathy and diabetic retinopathy. Following landmark 
studies like the IRMA2, RENAAL and IDNT trials,22–24 
RAS inhibition is widely accepted and recommended for 
patients with established micro- and macroalbuminuria, 
but the remaining issue of primary prevention is not yet 
solved. As evident from our literature search, only a few 
trials have reported this outcome, and not all were primar-
ily designed with this aim, which could be part of the 
explanation for the diverging results.
The biochemical aim for inhibition of the RAS is to 
reduce the deleterious effects of the angiotensin II peptide, 
most importantly exerting its effects by binding to the 
angiotensin II receptor subtype 1 (AT1R). The ACEi will 
inhibit the angiotensin-converting enzyme in converting 
angiotensin I to angiotensin II, thereby lowering substrate 
for the AT1R. The ARB binds directly to the AT1R, thereby 
Table 2. Blood pressure and hypertension status at baseline as reported in the six included trials (values are mean (SD)).
Study n Baseline SBP Baseline DBP Baseline MAP Hypertensive 
subjects (%)
Hypertension 
threshold (SD)
 Active Placebo Active Placebo Active Placebo Active Placebo mm Hg
 mm Hg mm Hg mm Hg mm Hg mm Hg mm Hg
Ravid et al.16 156 98  ± 4 
(84–105)
96 ± 4 
(84–104)
0 0 140/90 (MAP 
107)
ROADMAP5 4299 137 ± 16 136 ± 15 81 ± 10 80 ± 9 51 48 135/80
ADVANCE18 7986 145 ± 22 145 ± 21 81 ± 11 81 ± 11 68 69 140/90
DIRECT 24 1607 123 ± 9 123 ± 9 75 ± 6 76 ± 7 62 62 130/85
BENEDICT3 601 151 ± 15 152 ± 15 87 ± 8 88 ± 7 109 ± 9 109 ± 9 100 100 130/85
MICROHOPEa,17 2272 142 ± 20 142 ± 20 80 ± 11 79 ± 11 58 54 160/90
BP: blood pressure; DBP: diastolic blood pressure; MAP: mean arterial pressure; SBP: systolic blood pressure; SD: standard deviation.
aMean BP values from full study population including approximately 30% with baseline microalbuminuria.
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preventing angiotensin II from activating the receptor. 
Reduced glomerular capillary hypertension has been dem-
onstrated experimentally to minimise structural injury 
with mesangial expansion and fibrosis in the glomeruli 
leading to sclerosis, thereby slowing the development of 
glomerular leakage.25
Since Strippoli et al. published a systematic review on 
primary prevention of diabetic nephropathy in 2005,26 sev-
eral additional studies have been published, adding to the 
amount of evidence. Since larger studies are now availa-
ble, we excluded smaller studies (n<100) in an attempt to 
minimise publication and reporting bias. The first large 
Cochrane review by Strippoli et al. in 2006 did not inves-
tigate primary prevention of diabetic kidney disease, but 
recently the Cochrane report was updated by Lv et al.6 All 
antihypertensive treatment was analysed, despite the fact 
that most evidence and functional understanding regarding 
beneficial treatment come from RAS blocking drugs. 
Palmer et al.27 published a network meta-analysis investi-
gating blood pressure lowering agents in patients with dia-
betes and CKD. The overall conclusion was that ACEis 
and ARBs offer the best protection against progression to 
ESRD. The study included several relevant secondary out-
comes, i.e. regression of albuminuria, but did not evaluate 
first occurrence of microalbuminuria, and thus we cannot 
compare to the findings in our analysis. Catalá-López 
et al.28 performed a similar but more specific network 
meta-analysis on the effect on cardiorenal outcome of 
RAS blocking treatment in patients with diabetes, but inci-
dence of microalbuminuria was not included as outcome. 
Recently, Bangalore et al.29 published a somewhat differ-
ent analysis comparing RAS blocking treatment with other 
types of antihypertensive treatment in diabetes. It was con-
cluded that RAS offers no advantage compared other anti-
hypertensive drugs in relation to all-cause mortality, CVD 
events and renal risk. However, placebo-controlled trials 
were excluded, and renal outcome only consisted of 
ESRD, leaving out doubling of baseline creatinine which 
is a generally accepted endpoint and frequently used in 
renal trials. No data on occurrence of microalbuminuria 
was included. Importantly, for all the abovementioned 
analyses, the authors made no distinction between 
nephropathy in type 1 and type 2 diabetes, thereby mixing 
conditions with different pathologies.7–9
We therefore performed the present systematic review 
only in patients with type 2 diabetes and normoalbuminu-
ria, only comparing ACEis and ARBs to placebo, in order 
to get a cleaner picture of both patient populations and 
treatment. We hope this provides clinicians with more 
coherent information to use in a clinical setting.
Far from all patients with type 2 diabetes progress to 
diabetic nephropathy, and a future approach may be to 
select patients for early intervention based on risk mark-
ers. One such approach, using an urinary proteomic mul-
timarker risk pattern, is ongoing (www.EU-PRIORITY.
org), and may bring forth a more individualised preven-
tive treatment in normoalbuminuric patients with type 2 
diabetes.30
Our findings could have implications for future clinical 
practice. Side effects of RAS inhibitors are relatively mild 
and few in low-risk populations such as the study popula-
tions included, i.e. partly normotensive and well preserved 
kidney function. For instance, in the DIRECT study,4,31 
evaluating 5224 type 1 and type 2 diabetic patients, the 
occurrence of any serious adverse event, discontinuation 
due to adverse events or death were similar in the normo-
tensive and hypertensive patients treated with RAS inhibi-
tion or placebo. Many hypertensive patients with type 2 
diabetes will already be on RAS inhibitors, but extension 
of this to normotensive normoalbuminuric patients can 
now be contemplated. In addition, recent evidence from 
another meta-analysis suggests that RAS inhibitors can 
prevent and delay diabetic retinopathy in normotensive 
patients, further adding a reason for early initiation of 
treatment.32 Current guidelines2 do not recommend RAS 
inhibition in patients with normoalbuminuria, but our find-
ings alongside the meta-analysis by Wang et al.32,33 in dia-
betic retinopathy suggest that guidelines should be revised 
in order to further improve prevention of two major micro-
vascular diabetic complications.
Owing to different definitions of hypertension, and 
since the included papers did not stratify participants or 
results according to hypertensive status, we did not com-
pare normotensive and hypertensive subjects in our analy-
sis, and this may not be relevant if most patients with 
elevated blood pressure will have this treatment applied 
anyway. Although it may well be that the major part of the 
effect found in our analysis is reserved to hypertensive 
patients, we cannot rule out a similar effect in normoten-
sive subjects, making up approximately 38% of the ana-
lysed population. In fact many of the important 
renoprotective effects from RAS blocking treatment may 
well be related to other effects than those on systemic 
blood pressure, as seen in the IRMA 2, RENAAL and 
IDNT trials.22–24
Also we did not compare ACEi vs ARB due to data 
size, judging by the numbers needed in the comparative 
network meta-analysis by Palmer et al.27 and the doses 
used in the included studies were not investigated in 
detail. However, the ONTARGET study,34,35 the largest 
study so far, demonstrated that clinical effects are alike 
when compared head-to-head. There may be differences 
between optimal antiproteinuric doses between drugs 
that inhibit the RAS, and sometimes the optimal antipro-
teinuric dose is different from widely recommended anti-
hypertensive doses.36–38
The included six trials used different endpoint defini-
tions and methodology in relation to occurrence of micro-
albuminuria, but a recent paper looking at different 
endpoint definitions concludes that this has only minor 
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impact on the robustness of the outcome.39 The authors 
performed a post-hoc analysis of four randomised con-
trolled clinical trials and conclude that single urine collec-
tions at a study visit are sufficient to define a transition in 
albuminuria as endpoint in clinical trials. In addition, dif-
ferent ACEi/ARB treatments used may also add a certain 
degree of pharmacological heterogeneity, as seen in some 
of the few studies comparing different treatments in simi-
lar populations.40,41 However, in terms of effect on devel-
opment of microalbuminuria, there seems to be an effect of 
similar magnitude across different ACEi/ARBs.
We did not have the opportunity to analyse further sec-
ondary endpoints or safety and side effects along with the 
analysis of effect of ACEi/ARB treatment. This is an 
important limitation to our meta-analysis, especially if we 
want to promote this as standard early treatment of normo-
tensive, normoalbuminuric patients in future guidelines. 
However all-cause mortality was insignificantly reduced, 
which at least speaks for the overall safety of early inter-
vention. In addition, there are no clear signs from the 
reporting of adverse events in the included trials nor from 
a large trial in type 1 diabetes (the RASS trial)42 or in pre-
hypertension (the TROPHY study)43 that there is a clini-
cally significant increased frequency of hypotension and 
related side effects in normotensive populations treated 
with ACEi/ARBs. Depending on the definition of hyper-
tension, a large proportion of patients with type 2 diabetes 
will be hypertensive anyway, as seen during follow-up in 
the DIRECT 2 trial, so treating normotension may not a 
frequent occurrence. Rather, it may be important to ensure 
that patients with type 2 diabetes receive treatment with 
ACEi or ARB as the first drug, whether the indication is 
hypertension or primary or secondary prevention of micro-
vascular complications. It is however also important to 
point out that not all patients with type 2 diabetes will 
develop microalbuminuria, and not all patients diagnosed 
with nephropathy have true glomerular disease.7–9 In addi-
tion, it could have been relevant to include to include stud-
ies using renin inhibitors, another RAS blocking treatment, 
but as no studies using renin inhibition in primary preven-
tion have been performed or initiated, we did not include 
this in our review.
A future collaborative meta-analysis with individual 
patient-level data from the included six trials seems feasi-
ble and would allow for more detailed safety information, 
as well as time-to-event analyses for primary outcome. 
However, a comparison between one-stage and two-stage 
meta-analyses approach of clinical trials by Stewart et al.,44 
concluded that the two methods produce similar results.
Conclusions
In conclusion, we demonstrate that there is sufficient data 
available to conclude that inhibition of RAS using ACEis 
or ARBs can reduce the incidence of microalbuminuria, a 
risk marker for both renal disease and CVD, in patients 
with type 2 diabetes. This conclusion is, however, given 
with reservations since the populations included are heter-
ogenous and a full safety analysis was not available.
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